Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

9.92

Margin Of Safety %

-48

Put/Call OI Ratio

0.03

EPS Next Q Diff

-0.02

EPS Last/This Y

-0.44

EPS This/Next Y

0.2

Price

2

Target Price

8.03

Analyst Recom

1.4

Performance Q

88.68

Relative Volume

1.17

Beta

1.96

Ticker: GOSS




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-07GOSS1.250.040.0056450
2025-07-08GOSS1.270.040.0056518
2025-07-09GOSS1.3650.040.0056541
2025-07-10GOSS1.3650.040.0056562
2025-07-11GOSS1.350.040.0056563
2025-07-14GOSS1.530.040.0156466
2025-07-15GOSS1.4550.040.0057030
2025-07-16GOSS1.70.040.0057395
2025-07-17GOSS1.7150.040.0058815
2025-07-18GOSS1.70.040.0159040
2025-07-21GOSS1.760.040.0058282
2025-07-22GOSS1.7150.040.0658119
2025-07-23GOSS1.8750.040.0058028
2025-07-24GOSS1.770.040.0158771
2025-07-25GOSS1.850.040.1458717
2025-07-28GOSS1.9850.040.0058958
2025-07-29GOSS1.960.040.0059059
2025-07-30GOSS2.070.030.0070691
2025-07-31GOSS2.040.030.0069895
2025-08-01GOSS20.030.0069675
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-07GOSS1.25-183.8-95.9-0.69
2025-07-08GOSS1.27-183.8-98.4-0.69
2025-07-09GOSS1.36-183.8-107.2-0.69
2025-07-10GOSS1.36-183.8-96.9-0.69
2025-07-11GOSS1.36-183.8-94.5-0.69
2025-07-14GOSS1.53-183.8-116.2-0.69
2025-07-15GOSS1.45-183.8-87.0-0.69
2025-07-16GOSS1.66-183.8-118.9-0.69
2025-07-17GOSS1.71-183.8-100.4-0.69
2025-07-18GOSS1.70-183.8-94.5-0.69
2025-07-21GOSS1.76-183.8-101.1-0.69
2025-07-22GOSS1.72-183.8-92.8-0.69
2025-07-23GOSS1.87-183.8-109.0-0.69
2025-07-24GOSS1.78-183.8-88.3-0.69
2025-07-25GOSS1.84-183.8-100.8-0.69
2025-07-28GOSS1.99-183.8-108.3-0.69
2025-07-29GOSS1.96-183.6-94.2-0.69
2025-07-30GOSS2.08-183.6-105.0-0.69
2025-07-31GOSS2.04-183.6-92.5-0.69
2025-08-01GOSS2.00-183.6-92.5-0.69
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-07GOSS0.00-0.966.06
2025-07-08GOSS0.00-0.966.06
2025-07-09GOSS0.00-0.966.06
2025-07-10GOSS0.00-0.966.06
2025-07-11GOSS0.00-0.969.26
2025-07-14GOSS0.000.599.26
2025-07-15GOSS0.000.599.26
2025-07-16GOSS0.000.599.26
2025-07-17GOSS0.000.599.26
2025-07-18GOSS0.000.599.26
2025-07-21GOSS0.000.719.26
2025-07-22GOSS0.000.719.26
2025-07-23GOSS0.000.719.26
2025-07-24GOSS0.000.719.26
2025-07-25GOSS0.000.719.92
2025-07-28GOSS0.007.039.92
2025-07-29GOSS0.007.039.92
2025-07-30GOSS0.007.039.92
2025-07-31GOSS0.007.039.92
2025-08-01GOSS0.007.039.92
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.16

Avg. EPS Est. Current Quarter

-0.18

Avg. EPS Est. Next Quarter

-0.18

Insider Transactions

Institutional Transactions

7.03

Beta

1.96

Average Sales Estimate Current Quarter

4

Average Sales Estimate Next Quarter

5

Fair Value

1.05

Quality Score

17

Growth Score

33

Sentiment Score

92

Actual DrawDown %

86.8

Max Drawdown 5-Year %

-96.8

Target Price

8.03

P/E

Forward P/E

PEG

P/S

3.65

P/B

P/Free Cash Flow

EPS

-0.24

Average EPS Est. Cur. Y​

-0.69

EPS Next Y. (Est.)

-0.49

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-41.13

Relative Volume

1.17

Return on Equity vs Sector %

796.1

Return on Equity vs Industry %

814.7

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-92.5
Gossamer Bio, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 144
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
stock quote shares GOSS – Gossamer Bio, Inc. Stock Price stock today
news today GOSS – Gossamer Bio, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch GOSS – Gossamer Bio, Inc. yahoo finance google finance
stock history GOSS – Gossamer Bio, Inc. invest stock market
stock prices GOSS premarket after hours
ticker GOSS fair value insiders trading